NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer's Treatment
TAMPA, FL / ACCESS Newswire NeuroEM Therapeutics ®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with BlueLake.vc. The Series A round supports continued progress toward commercialization of NeuroEM's Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or Alzheimer's and other neurodegenerative diseases.
'BlueLake's support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer's dementia and other neurodegenerative diseases,' says Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'It fuels the tireless efforts of our researchers, clinicians, engineers, and the entire NeuroEM team to restore the hope and dignity Alzheimer's disease has already stolen from millions and to one day prevent millions more from facing this devastating diagnosis.'
The equity round is led by BlueLake Partner Jamie Rutledge, who also joins the NeuroEM Board of Directors. Rutledge focuses on early-stage investments in breakthrough technologies at BlueLake and is a seasoned technology investor and executive with deep expertise in strategic investment and innovation across the medical technology and consumer electronics sectors. He brings over 25 years of experience to NeuroEM, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo's Strategic Venture Capital and Open Innovation initiatives and directed technology scouting and strategic investments at Dyson.
'NeuroEM's pioneering, non-invasive approach to treating and preventing Alzheimer's represents exactly the kind of patented, deep tech innovation we champion at BlueLake – transformative, defensible, and grounded in scientific rigor. This approach to drug-free treatment and prevention of Alzheimer's holds tremendous promise in tackling a disease that has eluded effective solutions for decades,' said Rutledge. 'We're proud to support the advancement of this groundbreaking technology, and I'm personally honored to help guide NeuroEM as it brings innovative, non-invasive therapies to the forefront of neurodegenerative care.'
Adds Papageorgiou, 'Jamie's background in radio frequency systems, embedded devices, and product development aligns closely with our core technology, and his strategic insight will be a valuable asset as NeuroEM moves toward commercialization and broader market engagement.'
NeuroEM Therapeutics, a member of StartUp Health's Alzheimer's Moonshot Community ™, is committed to developing, clinically testing, and marketing its multi-patented TEMT-RF technologies that target and reduce cognitive decline and restore immune balance in the brain and blood while boosting energy production in brain cells – critical elements for optimal cognitive function. Early studies have demonstrated that, as an Alzheimer's treatment, TEMT-RF is safe, enhances cognitive function, and may potentially modify the disease itself.
The company's first commercial product, a lightweight cap designed for at-home use, is currently under development and has shown extraordinary promise in preclinical and clinical studies. Worn for an hour twice daily, the device uses short pulses of energy in specific ultra-high frequencies to deliver a transcranial electromagnetic treatment that improves key physical factors in the brain at the root of cognitive decline.
BlueLake Ventures invests in applied deep tech for the future of work and health, technology defined by significant barriers to entry, such as strong patent protection or specialized domain expertise. Its team consists of experienced operators who have built and scaled startup companies, held executive positions in multi-national corporations, built partnerships between startups and corporations, and deployed strategic venture capital in technology-driven businesses. By leveraging its expertise, resources, and networks, BlueLake aims to accelerate the growth of deep tech innovations that empower both businesses and consumers.
About NeuroEM Therapeutics ®
NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit neuroem.com.
Media Contact:
Liz Goar
NPC Creative Services
liz@npccs.com
SOURCE: NeuroEM Therapeutics
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
6 hours ago
Diabetes drug may cut migraine days in half with little weight loss: Study
Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.
Forbes
11 hours ago
- Forbes
How You Can Invest In Later-Stage Companies And Help Them Grow
Business investors meeting and signing documents It's fascinating to observe the journey of companies that have navigated past the initial startup phase. These businesses, having secured early-stage funding, often reach a point where their operations feel more stable. Yet, despite clearing those early hurdles, late-stage companies aren't entirely out of the woods. Their founders still frequently need funding to sustain momentum and fuel further growth. I've been particularly interested in this stage because, counterintuitively, securing that continued funding can sometimes be even trickier for late-stage ventures. You might assume early success would be a magnet for investors, but the reality is more nuanced. Investors are understandably more selective these days, especially with lingering anxieties about inflation and overall economic performance. And while a startup may have proven its business model works now, the question of its future viability looms large for potential backers. Venture capitalists understand that risk is inherent in backing any company. But they also don't want to sink their money into businesses where the ROI isn't there. Nor will they be attracted to companies with few (if any) competitive advantages. As I've seen many companies grapple with this crucial next step, it became clear that there are significant, mutually beneficial opportunities for business leaders to leverage their commercial and strategic expertise to help these later-stage companies not just survive, but truly thrive. Here are some ideas. Series C Financing Rounds Later-stage companies haven't made it to the IPO stage yet. However, these startups are past the seed, Series A and Series B funding rounds. Founders got the capital they needed to launch and gain traction. Now, they're looking to sell prospective investors shares to keep the momentum going. Series C financing typically involves purchasing preferred shares in a pre-IPO but established business. Preferred shares mean you have priority over common shareholders when it comes to staking a claim on the company's earnings. In other words, preferred shareholders are first in line when the business is sold and dividends are paid. Individuals, investment, and private equity firms can participate in Series C financing rounds. Yet, co-investor family offices and equity firms are shifting gears. Whether it's participating in Series C rounds or another avenue, sector specialization is rising. Sixty-eight percent of investors are focusing on sectors they have experience in instead of a general approach. Many investors are focusing on their ability to add value to a deal, with commercial relationships and strategic partnerships, and even key executive hires. They're also concentrating on industries, such as AI, cybersecurity, logistics and government tech. Secondary market transactions represent another investment strategy that's attracting interest. Secondary Markets Secondary market transactions involve buying shares in a later-stage company from current owners. These shareholders could be employees and those who got in during the business's seed stage. It's not the same as buying shares during an IPO because these shares aren't available for trading on the stock exchange. What secondary markets do is allow early investors to realize returns before the company goes public or is sold through an acquisition. Because later-stage companies aren't public yet, investors can often secure shares for a discount. The potential for future value and growth is there when (and if) the business goes public. After Series C, the risk of startup failure also decreases dramatically. The failure rate is around 1%, whereas it hovers at 60% between pre-seed and Series A. In a macroeconomy rife with uncertainty, less risky bets are attractive to investors. And the growth of secondary market transactions seems to back up this sentiment. Global secondary transaction volume rose to $128 billion in 2021, while surpassing $100 billion in 2022 and 2023. Online Platforms And Private Equity Firms Online platforms and private equity firms can connect you with investment opportunities outside the traditional markets. If you want to put your money in later-stage companies, specialized platforms and equity firms may provide access. Not everyone has existing relationships with pre-IPO businesses. Even for those who do, these investors might want to broaden their knowledge and portfolio mix with additional opportunities. For instance, Hiive provides access to investments in private companies while SPLYCAP is a private equity firm connecting investors with growth-stage and late-stage businesses. These connections can extend beyond the numbers, including adding value to a firm's commercial and strategic direction. Through its understanding of the AI firm Nanotronics, the company gained a new chief operating officer with 30 years of tech and construction industry experience. As Nanotronics CEO Matthew Putman says, he's 'seen companies and investors connect in ways that feel truly special, beyond just financials. It's about sharing a purpose and growing together, lifting both a fund and my company.' With most investors having a neutral sentiment about the overall market, later-stage companies offering a shared meaning can stand out by leveraging commercial relationships in their network. And online platforms and private equity firms could be the gateway to building those relationships. Helping Later-Stage Companies Grow No matter what stage businesses are in, funding is a critical component of success. Without cash flow, operations stall and services cannot be delivered. More importantly, companies are unable to get to the next milestone. For late-stage firms, the next milestone is usually some type of exit, either an IPO or a sale to a larger company. As investors become more discerning, later-stage businesses can't rely on blanket or generalist funding sources. While undoubtedly less risky than a pre-seed startup, late-stage companies still need to offer investors a distinctive opportunity. Making connections between investors' shared expertise and purpose is one way to stand out. Investment that extends beyond capital raising, elevating companies with proven promise to the next level, is where the real magic lies.
Yahoo
12 hours ago
- Yahoo
Rise in VC activity tees up ‘strong year' for medtech funding: PitchBook
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Increases in venture capital investments have positioned 2025 to be a 'strong year for global medtech funding,' according to a report from market data research firm PitchBook. First quarter VC funding totaled $4.1 billion, the highest it has been since 2022. The number of confirmed transactions hit 216, reversing a four-quarter decline. However, the uptick in medtech mergers and acquisitions that PitchBook predicted under the second Trump administration has yet to emerge, and antitrust regulators are still challenging deals. Medtech VC activity fell in both 2022 and 2023, according to PitchBook. Last year brought signs that the market might be bottoming. The number of VC investments fell for the third year in a row, but the amount of funding was higher than in 2023. Signs of a VC recovery continued into the first quarter of 2025, when the $260 million investment in whole-body-imaging startup Neko Health was the largest of 11 rounds worth $100 million or more. With Elon Musk's brain implant startup Neuralink raising $650 million this month, PitchBook said preliminary data for the second quarter shows more than $3 billion of medtech VC funding so far. VC exits are rare, though. PitchBook said there were no significant medtech VC exits in the first quarter, and the total exit value remained roughly in line with the previous two quarters. Total exit value in recent years has been driven by rare big deals, such as Tempus AI's initial public offering in 2024 and the $6 billion acquisition of Athelas in 2023. PitchBook highlighted three notable exits that closed in the first quarter: Beta Bionics' IPO, Hologics' $350 million takeover of Gynesonics and Boston Scientific's $540 million acquisition of SoniVie. The level of activity has fallen short of PitchBook's expectations. 'Our earlier thesis that the new U.S. presidential administration's more lenient regulatory stance would catalyze M&A activity has yet to play out, as broader market turbulence in early 2025 has complicated dealmaking conditions across sectors,' PitchBook said. 'Additionally, regulatory resistance remains a headwind.' PitchBook cited the Federal Trade Commission's legal challenge to the $627 million private equity buyout of Surmodics as evidence of ongoing regulatory resistance. The FTC challenged the deal on the grounds it 'would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition.' Recommended Reading Medtech venture investment recovery continues, but startup M&A remains limited: Pitchbook Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
